Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marie Gerhard-Herman is active.

Publication


Featured researches published by Marie Gerhard-Herman.


Journal of the American College of Cardiology | 2002

Guidelines for the Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery A Report of the International Brachial Artery Reactivity Task Force

Mary C. Corretti; Todd J. Anderson; Emelia J. Benjamin; David S. Celermajer; Francois Charbonneau; Mark A. Creager; John Deanfield; Helmut Drexler; Marie Gerhard-Herman; David M. Herrington; Patrick Vallance; Joseph A. Vita; Robert A. Vogel

Endothelial function is thought to be an important factor in the pathogenesis of atherosclerosis, hypertension and heart failure. In the 1990s, high-frequency ultrasonographic imaging of the brachial artery to assess endothelium-dependent flow-mediated vasodilation (FMD) was developed. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of vasomotor function. The noninvasive nature of the technique allows repeated measurements over time to study the effectiveness of various interventions that may affect vascular health. However, despite its widespread use, there are technical and interpretive limitations of this technique. State-of-the-art information is presented and insights are provided into the strengths and limitations of high-resolution ultrasonography of the brachial artery to evaluate vasomotor function, with guidelines for its research application in the study of endothelial physiology.


Circulation | 2014

2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Lee A. Fleisher; Kirsten E. Fleischmann; Andrew D. Auerbach; Susan Barnason; Joshua A. Beckman; Biykem Bozkurt; Victor G. Dávila-Román; Marie Gerhard-Herman; Thomas A. Holly; Garvan C. Kane; Joseph E. Marine; M. Timothy Nelson; Crystal C. Spencer; Annemarie Thompson; Henry H. Ting; Barry F. Uretsky; Duminda N. Wijeysundera

Jeffrey L. Anderson, MD, FACC, FAHA, Chair Jonathan L. Halperin, MD, FACC, FAHA, Chair-Elect Nancy M. Albert, PhD, RN, FAHA Biykem Bozkurt, MD, PhD, FACC, FAHA Ralph G. Brindis, MD, MPH, MACC Lesley H. Curtis, PhD, FAHA David DeMets, PhD[¶¶][1] Lee A. Fleisher, MD, FACC, FAHA Samuel


The New England Journal of Medicine | 2008

Phenotype and course of Hutchinson-Gilford progeria syndrome

Melissa Merideth; Leslie B. Gordon; Sarah Clauss; Vandana Sachdev; Ann C.M. Smith; Monique B. Perry; Carmen C. Brewer; Christopher Zalewski; H. Jeffrey Kim; Beth Solomon; Brian P. Brooks; Lynn H. Gerber; Maria L. Turner; Demetrio L. Domingo; Thomas C. Hart; Jennifer Graf; James C. Reynolds; Andrea Gropman; Jack A. Yanovski; Marie Gerhard-Herman; Francis S. Collins; Elizabeth G. Nabel; Richard O. Cannon; William A. Gahl; Wendy J. Introne

BACKGROUND Hutchinson-Gilford progeria syndrome is a rare, sporadic, autosomal dominant syndrome that involves premature aging, generally leading to death at approximately 13 years of age due to myocardial infarction or stroke. The genetic basis of most cases of this syndrome is a change from glycine GGC to glycine GGT in codon 608 of the lamin A (LMNA) gene, which activates a cryptic splice donor site to produce abnormal lamin A; this disrupts the nuclear membrane and alters transcription. METHODS We enrolled 15 children between 1 and 17 years of age, representing nearly half of the worlds known patients with Hutchinson-Gilford progeria syndrome, in a comprehensive clinical protocol between February 2005 and May 2006. RESULTS Clinical investigations confirmed sclerotic skin, joint contractures, bone abnormalities, alopecia, and growth impairment in all 15 patients; cardiovascular and central nervous system sequelae were also documented. Previously unrecognized findings included prolonged prothrombin times, elevated platelet counts and serum phosphorus levels, measured reductions in joint range of motion, low-frequency conductive hearing loss, and functional oral deficits. Growth impairment was not related to inadequate nutrition, insulin unresponsiveness, or growth hormone deficiency. Growth hormone treatment in a few patients increased height growth by 10% and weight growth by 50%. Cardiovascular studies revealed diminishing vascular function with age, including elevated blood pressure, reduced vascular compliance, decreased ankle-brachial indexes, and adventitial thickening. CONCLUSIONS Establishing the detailed phenotype of Hutchinson-Gilford progeria syndrome is important because advances in understanding this syndrome may offer insight into normal aging. Abnormal lamin A (progerin) appears to accumulate with aging in normal cells. (ClinicalTrials.gov number, NCT00094393.)


Journal of the American College of Cardiology | 2017

2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Marie Gerhard-Herman; Heather L. Gornik; Coletta Barrett; Neal R. Barshes; Matthew A. Corriere; Douglas E. Drachman; Lee A. Fleisher; Francis Gerry R. Fowkes; Naomi M. Hamburg; Scott Kinlay; R. Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W. Olin; Rajan A.G. Patel; Judith G. Regensteiner; Andres Schanzer; Mehdi H. Shishehbor; Kerry J. Stewart; Diane Treat-Jacobson; M. Eileen Walsh

Jonathan L. Halperin, MD, FACC, FAHA, Chair Glenn N. Levine, MD, FACC, FAHA, Chair-Elect Sana M. Al-Khatib, MD, MHS, FACC, FAHA Kim K. Birtcher, PharmD, MS, AACC Biykem Bozkurt, MD, PhD, FACC, FAHA Ralph G. Brindis, MD, MPH, MACC Joaquin E. Cigarroa, MD, FACC Lesley H. Curtis, PhD, FAHA


Arteriosclerosis, Thrombosis, and Vascular Biology | 2010

Cardiovascular Pathology in Hutchinson-Gilford Progeria: Correlation With the Vascular Pathology of Aging

Michelle Olive; Ingrid A. Harten; Richard N. Mitchell; Jeanette Beers; Karima Djabali; Kan Cao; Michael R. Erdos; Cecilia D. Blair; Birgit Funke; Leslie B. Smoot; Marie Gerhard-Herman; Jason T. Machan; Robert Kutys; Renu Virmani; Francis S. Collins; Thomas N. Wight; Elizabeth G. Nabel; Leslie B. Gordon

Objective—Children with Hutchinson-Gilford progeria syndrome (HGPS) exhibit dramatically accelerated cardiovascular disease (CVD), causing death from myocardial infarction or stroke between the ages of 7 and 20 years. We undertook the first histological comparative evaluation between genetically confirmed HGPS and the CVD of aging. Methods and Results—We present structural and immunohistological analysis of cardiovascular tissues from 2 children with HGPS who died of myocardial infarction. Both had features classically associated with the atherosclerosis of aging, as well as arteriolosclerosis of small vessels. In addition, vessels exhibited prominent adventitial fibrosis, a previously undescribed feature of HGPS. Importantly, although progerin was detected at higher rates in the HGPS coronary arteries, it was also present in non-HGPS individuals. Between the ages of 1 month and 97 years, progerin staining increased an average of 3.34% per year (P<0.0001) in coronary arteries. Conclusion—We find concordance among many aspects of cardiovascular pathology in both HGPS and geriatric patients. HGPS generates a more prominent adventitial fibrosis than typical CVD. Vascular progerin generation in young non-HGPS individuals, which significantly increases throughout life, strongly suggests that progerin has a role in cardiovascular aging of the general population.


Proceedings of the National Academy of Sciences of the United States of America | 2012

Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome

Leslie B. Gordon; Monica E. Kleinman; David T. Miller; Donna Neuberg; Anita Giobbie-Hurder; Marie Gerhard-Herman; Leslie B. Smoot; Catherine M. Gordon; Robert H. Cleveland; Brian D. Snyder; Brian Fligor; W. Robert Bishop; Paul Statkevich; Amy Regen; Andrew L. Sonis; Susan Riley; Christine Ploski; Annette Correia; Nicolle Quinn; Nicole J. Ullrich; Ara Nazarian; Marilyn G. Liang; Susanna Y. Huh; Armin Schwartzman; Mark W. Kieran

Hutchinson–Gilford progeria syndrome (HGPS) is an extremely rare, fatal, segmental premature aging syndrome caused by a mutation in LMNA that produces the farnesylated aberrant lamin A protein, progerin. This multisystem disorder causes failure to thrive and accelerated atherosclerosis leading to early death. Farnesyltransferase inhibitors have ameliorated disease phenotypes in preclinical studies. Twenty-five patients with HGPS received the farnesyltransferase inhibitor lonafarnib for a minimum of 2 y. Primary outcome success was predefined as a 50% increase over pretherapy in estimated annual rate of weight gain, or change from pretherapy weight loss to statistically significant on-study weight gain. Nine patients experienced a ≥50% increase, six experienced a ≥50% decrease, and 10 remained stable with respect to rate of weight gain. Secondary outcomes included decreases in arterial pulse wave velocity and carotid artery echodensity and increases in skeletal rigidity and sensorineural hearing within patient subgroups. All patients improved in one or more of these outcomes. Results from this clinical treatment trial for children with HGPS provide preliminary evidence that lonafarnib may improve vascular stiffness, bone structure, and audiological status.


Circulation | 2014

2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery: Executive Summary

Lee A. Fleisher; Kirsten E. Fleischmann; Andrew D. Auerbach; Susan Barnason; Joshua A. Beckman; Biykem Bozkurt; Victor G. Dávila-Román; Marie Gerhard-Herman; Thomas A. Holly; Garvan C. Kane; Joseph E. Marine; M. Timothy Nelson; Crystal C. Spencer; Annemarie Thompson; Henry H. Ting; Barry F. Uretsky; Duminda N. Wijeysundera

Preamble 2216 1. Introduction 2217 2. Clinical Risk Factors: Recommendations 2220 3. Approach to Perioperative Cardiac Testing 2221 4. Supplemental Preoperative Evaluation: Recommendations 2221 5. Perioperative Therapy: Recommendations 2224 6. Anesthetic Consideration and Intraoperative Management: Recommendations 2228 7. Surveillance and Management for Perioperative MI: Recommendations 2229 8. Future Research Directions 2230 Appendix 1. Author Relationships With Industry and Other Entities (Relevant) 2237 Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant) 2239 Appendix 3. Related Recommendations From Other CPGs 2244 References 2230 The American College of Cardiology (ACC) and the American Heart Association (AHA) are committed to the prevention and management of cardiovascular diseases through professional education and research for clinicians, providers, and patients. Since 1980, the ACC and AHA have shared a responsibility to translate scientific evidence into clinical practice guidelines (CPGs) with recommendations to standardize and improve cardiovascular health. These CPGs, based on systematic methods to evaluate and classify evidence, provide a cornerstone of quality …


Vascular Medicine | 2006

Guidelines for noninvasive vascular laboratory testing: a report from the American Society of Echocardiography and the Society for Vascular Medicine and Biology

Marie Gerhard-Herman; Julius M. Gardin; Michael R. Jaff; Emile R. Mohler; Mary J. Roman; Tasneem Z. Naqvi

Accompanying the rapid growth of interest in percutaneous vascular interventions, there has been increasing interest among cardiologists in performing noninvasive vascular testing using ultrasound. In an attempt to provide recommendations on the best practices in vascular laboratory testing, this report has been prepared by a writing group from the American Society of Echocardiography (ASE) and the Society for Vascular Medicine and Biology. The document summarizes principles integral to vascular duplex ultrasound--including color Doppler, spectral Doppler waveform analysis, power Doppler, and the use of contrast. Appropriate indications and interpretation of carotid artery, renal artery, abdominal aorta, and peripheral artery ultrasound imaging are described. A dedicated section summarizes noninvasive techniques for physiologic vascular testing of the lower extremity arteries--including measurement of segmental pressures and pulse volume plethysmography. The use of exercise testing in the evaluation of peripheral artery disease, ultrasound evaluation of the lower extremities after percutaneous revascularization, and the diagnosis and management of iatrogenic pseudoaneurysm (PSA) is also discussed. A section on the important topic of vascular laboratory accreditation is included. Finally, additional details regarding proper technique for performance of the various vascular tests and procedures are included in the Appendix.


Hypertension | 2006

Automated Oscillometric Determination of the Ankle–Brachial Index Provides Accuracy Necessary for Office Practice

Joshua A. Beckman; Caitlin O. Higgins; Marie Gerhard-Herman

Peripheral arterial disease (PAD) remains underdiagnosed by primary care and cardiovascular physicians. The office-based assessment of PAD is limited by the need for specialized equipment and the time required for performance of the ankle–brachial index (ABI). We explored whether the accuracy of automated ABI measurement by oscillometry compared favorably with the gold-standard method using continuous-wave Doppler ultrasound. Consecutive patients referred to our university hospital noninvasive vascular laboratory for ABI measurement were invited for participation. Of 205 patients, 201 participated, including 55 with PAD. The ABI was measured by automated oscillometry and Doppler ultrasound. The test of trends revealed a correlation coefficient of 0.78 in the left leg and 0.78 in the right leg (P<0.01 for both). The mean ABI difference between methods was 0.04±0.01 and 0.06±0.01, respectively, in the left and right legs. The differences between the methods followed a normal distribution. Oscillometric determination of the ABI provides an accurate determination of the ABI in an outpatient population. Our findings show automated oscillometry to be a reliable and easier method of ABI measurement, lowering the barrier to incorporation of this diagnostic test into clinical practice.


Journal of Clinical and Experimental Neuropsychology | 2009

Vascular and cognitive functions associated with cardiovascular disease in the elderly.

Ronald A. Cohen; Athena Poppas; Daniel E. Forman; Karin F. Hoth; Andreana P. Haley; John Gunstad; Angela L. Jefferson; David F. Tate; Robert H. Paul; Lawrence H. Sweet; Mokato Ono; Beth A. Jerskey; Marie Gerhard-Herman

This study examines the relationship between systemic vascular function, neurocognitive performance, and structural brain abnormalities on magnetic resonance imaging (MRI) among geriatric outpatients with treated, stable cardiovascular disease and no history of neurological illness (n = 88, ages 56–85 years). Vascular function was assessed by cardiac ejection fraction and output, sequential systolic and diastolic blood pressures, flow mediated brachial artery reactivity (BAR), and carotid intima media thickness (IMT). White matter hyperintensities (WMH) on MRI were quantified and examined relative to cognitive and vascular function. Principal component analysis revealed two primary vascular components: one associated with cardiac function, the other with atherosclerotic burden/endothelial dysfunction. Both factors were significantly associated with cognitive function and WMH volume. Reduced systolic variability and increased IMT were most strongly related to reduced attention, executive function, and information-processing speed. These findings suggest the possibility that systemic vascular indices may provide proxy measures of cerebrovascular dysfunction and reinforce the importance of achieving greater understanding of interaction between systemic vascular disease and brain dysfunction among elderly people with cardiovascular disease.

Collaboration


Dive into the Marie Gerhard-Herman's collaboration.

Top Co-Authors

Avatar

Emile R. Mohler

American College of Cardiology

View shared research outputs
Top Co-Authors

Avatar

Heather L. Gornik

American College of Cardiology

View shared research outputs
Top Co-Authors

Avatar

Frank J. Rybicki

Ottawa Hospital Research Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael R. Jaff

Newton Wellesley Hospital

View shared research outputs
Top Co-Authors

Avatar

Joshua A. Beckman

Vanderbilt University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sanjeeva P. Kalva

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar

Christopher J. François

University of Wisconsin-Madison

View shared research outputs
Researchain Logo
Decentralizing Knowledge